Theriva Biologics, Inc. has released its financial results for the third quarter of 2026, marking a significant moment for the company as it continues to advance its clinical programs. The report, filed on November 12, 2026, highlights the company's commitment to developing innovative cancer therapies and outlines key operational milestones.
The third-quarter report comes at a crucial time for Theriva, which is focused on the development of therapeutics aimed at treating cancer and related diseases. The company is currently engaged in the VIRAGE2 clinical trial, which is expected to complete patient enrollment by the end of the fourth quarter of 2026. Initial data from this trial is anticipated by the third quarter of 2027.
Background
Theriva Biologics, Inc., incorporated in Nevada, operates in the pharmaceutical preparations sector (SIC: 2834). The company trades on the NYSE American under the ticker symbol TOVX. Recent filings include a 10-Q and another 8-K, both submitted on November 12, 2026, indicating ongoing financial and operational updates.
What the Filing Says
In the filing, Theriva Biologics reported that it has made significant progress in its clinical trials. The company stated, "Patient enrollment and dosing in the VIRAGE2 trial is progressing well, and we anticipate completing enrollment by the end of the fourth quarter of this year." This trial aims to evaluate the safety and efficacy of VCN-01 in combination with standard chemotherapy for metastatic pancreatic cancer.
Additionally, the company completed the sale of SYN-004 (ribaxamase) and its related portfolio to Biossil Labs Inc. for an upfront payment of $350,000, with potential milestones and royalties that could total up to $91 million. This strategic move reflects Theriva's focus on maximizing value from its legacy programs while concentrating on its lead product.
Impact
The developments outlined in the filing may significantly impact various stakeholders, including patients, healthcare providers, and investors in the pharmaceutical sector. The successful advancement of the VIRAGE2 trial could lead to new treatment options for patients suffering from metastatic pancreatic cancer, a group with high unmet medical needs. Investors and analysts will likely monitor Theriva's progress closely, as it could set a precedent for other companies in the pharmaceutical preparations industry.
What's Next
Looking ahead, Theriva Biologics is set to continue its focus on the VIRAGE2 trial, with initial data expected by the third quarter of 2027. The company is also evaluating strategic alternatives to maximize shareholder value, indicating that further developments may be announced in the near future. The filing does not specify any upcoming votes or additional filings beyond the current report.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










